Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- The Rosen Law Firm PAROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- Снижение массы тела на 19,3 % к 48-й неделе -- данные исследования фазы III препарата Olatorepatide, двойного селективного агониста ГПП-1/ГИП компании Hansoh, представлены на EASDМИЛАН, 3 октября 2026 г. -- С 28 сентября по 2 октября 2026 года в Милане, Италия, проходит ежегодная конференция ассоциации European Association for the Study of Diabetes (EASD). Разработанный компанией Hansoh Pharma двойной селективный агонист рецепторов глюкагоноподобного...
- Ractigen TherapeuticsRactigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular DystrophyFirst clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,...
- CVS HealthAetna 2027 Medicare plans offer reliable, affordable access to care & member supportCompanies: CVS HealthPlans designed to provide member value and access to care: $0 copays on Tier 1 drugs and covered vaccines at in-network pharmacies* $0 copays for annual physicals, colonoscopies and mammograms at in-network providers $0 copays for annual Healthy Home Visit from a licensed Signify Health...
- Antengene Corporation LimitedAntengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- Grammy-Winning Bassist Stanley Clarke Reflects on Losing Friends to Drugs and the Mentor Who Changed His LifeStanley Clarke recalls how jazz legend Chick Corea helped him step away from drugs and introduced him to Dianetics: The Modern Science of Mental Health.
- XtalPi Inc.XtalPi Advances Hair Loss Drug Program into IND-Enabling StudiesThe proprietary program targets a lactate–autophagy pathway to reactivate quiescent hair follicle stem cells. In a mouse model, a candidate achieved a hair-growth score comparable to that of 5% topical minoxidil at just 1/100 of the comparator's concentration. The milestone builds on the...
- NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERSNOMAD Power Solutions, Inc. ("NOMAD" or the "Company") (Nasdaq: NMAD) (formerly LIXTE Biotechnology Holdings), a provider of transportable, utility-grade battery energy storage systems through its wholly owned subsidiary NOMAD Transportable Power Systems, today announced that its Special Meeting of Stockholders (the “Special Meeting”), reconvened on October 2, 2026, was adjourned without conducting any business. The Special Meeting will reconvene on October 30, 2026, at 1:00 PM Eastern Time.
- The Rosen Law Firm PAROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
- THE ROSEN LAW FIRM, P. A.ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitRosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff...
- Novo provides update on the denecimig Biologics License Application (BLA) in the USCompanies: Novo NordiskBagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.